Drug Profile
PR1 peptide vaccine
Alternative Names: NSC 698102Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer The Vaccine Company
- Class Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 30 Sep 2013 Discontinued - Phase-II for Chronic myeloid leukaemia in USA (SC)
- 30 Sep 2013 Discontinued - Phase-II for Myelodysplastic syndromes in USA (SC)
- 30 Sep 2013 Discontinued - Phase-III for Acute myeloid leukaemia in USA (SC)